Literature DB >> 12377257

Canine leishmaniasis: epidemiological risk and the experimental model.

Javier Moreno1, Jorge Alvar.   

Abstract

Increasing risk factors are making zoonotic visceral leishmaniasis a growing public health concern in many countries. Domestic dogs constitute the main reservoir of Leishmania infantum and Leishmania chagasi, and play a key role in the transmission to humans. New reagents and tools allow the detailed investigation of canine leishmaniasis, permitting the monitoring of the immunological status of dogs in both natural and experimental infections. Such studies are essential to determine the basis of the canine protective immune response and to establish a laboratory model, a significant aspect for the development of vaccines against canine leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12377257     DOI: 10.1016/s1471-4922(02)02347-4

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  126 in total

1.  The effect of removing potentially infectious dogs on the numbers of canine Leishmania infantum infections in an endemic area with high transmission rates.

Authors:  Gabriel Grimaldi; Antonio Teva; Claudiney B Santos; Adelson L Ferreira; Aloísio Falqueto
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  Qualitative and quantitative immunohistochemical evaluation of iNOS expression in the spleen of dogs naturally infected with Leishmania chagasi.

Authors:  Fernando Rocha dos Santos; Paula Melo Abreu Vieira; Rodrigo Correa-Oliveira; Rodolfo Cordeiro Giunchetti; Claudia Martins Carneiro; Alexandre Barbosa Reis; Luiz Cosme Cotta Malaquias
Journal:  Parasitol Res       Date:  2010-12-29       Impact factor: 2.289

3.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

4.  The use of spatial analysis to estimate the prevalence of canine leishmaniasis in Greece and Cyprus to predict its future variation and relate it to human disease.

Authors:  Dimitra Sifaki-Pistola; Pantelis Ntais; Vasiliki Christodoulou; Apostolos Mazeris; Maria Antoniou
Journal:  Am J Trop Med Hyg       Date:  2014-06-23       Impact factor: 2.345

5.  Canine leishmaniasis: the key points for qPCR result interpretation.

Authors:  Verónica Martínez; Javier Quilez; Armand Sanchez; Xavier Roura; Olga Francino; Laura Altet
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

6.  Fast high yield of pure Leishmania (Leishmania) infantum axenic amastigotes and their infectivity to mouse macrophages.

Authors:  Juliana Dias Costa; Renata Soares; Léa Cysne Finkelstein; Suzana Côrte-Real; Maria de Nazareth Meirelles; Renato Porrozzi
Journal:  Parasitol Res       Date:  2009-03-18       Impact factor: 2.289

7.  Evaluation of the influence of tissue parasite density on hematological and phenotypic cellular parameters of circulating leukocytes and splenocytes during ongoing canine visceral leishmaniasis.

Authors:  L L Guerra; A Teixeira-Carvalho; R C Giunchetti; O A Martins-Filho; A B Reis; R Corrêa-Oliveira
Journal:  Parasitol Res       Date:  2008-11-05       Impact factor: 2.289

8.  Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs.

Authors:  Yasuyuki Goto; Randall F Howard; Ajay Bhatia; Joelma Trigo; Maria Nakatani; Eduardo M Netto; Steven G Reed
Journal:  Vet Parasitol       Date:  2008-11-05       Impact factor: 2.738

9.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

10.  Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Authors:  J Moreno; J Nieto; S Masina; C Cañavate; I Cruz; C Chicharro; E Carrillo; S Napp; C Reymond; P M Kaye; D F Smith; N Fasel; J Alvar
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.